Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
CT-2106, a camptothecin (CPT) conjugate, is a new generation of topoisomerase I inhibitors
designed to deliver higher, more effective chemotherapy to tumor tissue with less toxicity to
normal tissues. The objective of this study is to determine the dose limiting toxicities,
safety profile and antitumor activity of CT-2016 in combination with 5-FU and folic acid for
the treatment of colorectal cancer.